These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10351145)

  • 1. Update on leucocyte depletion of blood components by filtration.
    Pietersz RN; van der Meer PF; Seghatchian MJ
    Transfus Sci; 1998 Dec; 19(4):321-8. PubMed ID: 10351145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP).
    Chamfly V
    Transfus Sci; 1998 Dec; 19(4):333-42. PubMed ID: 10351148
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection.
    Rawal BD; Davis RE; Busch MP; Vyas GN
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):36-41. PubMed ID: 2134639
    [No Abstract]   [Full Text] [Related]  

  • 4. Perspective on Nordic views on selective/universal leukodepletion.
    Flesland O
    Transfus Sci; 1998 Dec; 19(4):355-7. PubMed ID: 10351154
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies.
    Seghatchian MJ; Krailadsiri P
    Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of leukocyte-reduced blood components.
    Miller JP; Mintz PD
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing effective working partnership with manufacturers.
    Pujol-Reyz A
    Transfus Sci; 1998 Dec; 19(4):375-6. PubMed ID: 10351161
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukocyte reduction in blood component therapy.
    Lane TA; Anderson KC; Goodnough LT; Kurtz S; Moroff G; Pisciotto PT; Sayers M; Silberstein LE
    Ann Intern Med; 1992 Jul; 117(2):151-62. PubMed ID: 1605430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WBC filtration of whole blood after prolonged storage at ambient temperature by use of an in-line filter collection system.
    Shinar E; Prober G; Yahalom V; Michlin H
    Transfusion; 2002 Jun; 42(6):734-7. PubMed ID: 12147026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.
    Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462
    [No Abstract]   [Full Text] [Related]  

  • 11. Leukoreduction of blood components.
    Dzik WH
    Curr Opin Hematol; 2002 Nov; 9(6):521-6. PubMed ID: 12394176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte depletion of cellular blood components.
    Lane TA
    Curr Opin Hematol; 1994 Nov; 1(6):443-51. PubMed ID: 9371321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Why remove leukocytes from labile blood products in 1995?].
    Andreu G; Belhocine R; Klaren J; Fretz C; Lejus C
    Transfus Clin Biol; 1996; 3(1):57-74. PubMed ID: 8640315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of central analysis of leucocyte depletion quality control data within the National Blood Service, England.
    Beckman N; Cardigan R; Wallington T; Williamson LM
    Vox Sang; 2002 Aug; 83(2):110-8. PubMed ID: 12201840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukodepleted blood components: definition of a standard.
    Andreu G; Masse M; Royer SD; Tardivel R
    Transfus Sci; 1998 Dec; 19(4):381-3. PubMed ID: 10351163
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components.
    Dumont LJ
    Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential clinical benefits and cost savings of universal leucocyte-depletion of blood components.
    Murphy MF
    Transfus Sci; 1998 Dec; 19(4):343-6. PubMed ID: 10351149
    [No Abstract]   [Full Text] [Related]  

  • 18. Universal leucodepletion--practical and regulatory consequences.
    Barrowcliffe TW
    Transfus Sci; 1998 Dec; 19(4):361. PubMed ID: 10351156
    [No Abstract]   [Full Text] [Related]  

  • 19. Leukocyte-depleted blood. A comparison of filtration techniques.
    Mijović V; Brozović B; Hughes AS; Davies TD
    Transfusion; 1983; 23(1):30-2. PubMed ID: 6829055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International views on universal leucodepletion: the perspective in The Netherlands.
    de Wit HC
    Transfus Sci; 1998 Dec; 19(4):353-4. PubMed ID: 10351153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.